Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
Certara (NASDAQ: CERT) has appointed Dr. Adrian McKemey as President of Drug Development Solutions, effective March 3rd, 2025. McKemey, who previously served as head of Enterprise Transformation at IQVIA and Senior VP of R&D Strategy Solutions at Quintiles, brings over 25 years of experience in research and development.
The appointment is part of a planned leadership transition, with Patrick Smith, PharmD, moving to the role of Senior Vice President of Translational Sciences. McKemey holds a BSc and PhD in High Energy Nuclear Particle Physics from the University of London, and previously worked as a Principal at Boston Consulting Group's Life Sciences practice.
The company aims to leverage McKemey's expertise to accelerate growth in its biosimulation and scientific services for life sciences clients globally, focusing on improving drug development processes and portfolio decision-making through in silico models.
Certara (NASDAQ: CERT) ha nominato Dr. Adrian McKemey come Presidente delle Soluzioni per lo Sviluppo Farmaceutico, a partire dal 3 marzo 2025. McKemey, che in precedenza ha ricoperto il ruolo di responsabile della Trasformazione Aziendale presso IQVIA e Vicepresidente Senior delle Soluzioni Strategiche R&D presso Quintiles, porta con sé oltre 25 anni di esperienza nella ricerca e sviluppo.
Questa nomina fa parte di una transizione di leadership pianificata, con Patrick Smith, PharmD, che passerà al ruolo di Vicepresidente Senior delle Scienze Traslazionali. McKemey ha conseguito una laurea e un dottorato in Fisica delle Particelle Nucleari ad Alta Energia presso l'Università di Londra e ha lavorato in precedenza come Principal nella pratica delle Scienze della Vita del Boston Consulting Group.
L'azienda mira a sfruttare l'expertise di McKemey per accelerare la crescita dei suoi servizi di biosimulazione e scientifici per i clienti delle scienze della vita a livello globale, concentrandosi sul miglioramento dei processi di sviluppo farmaceutico e sulla decisione di portafoglio attraverso modelli in silico.
Certara (NASDAQ: CERT) ha nombrado Dr. Adrian McKemey como Presidente de Soluciones de Desarrollo de Medicamentos, a partir del 3 de marzo de 2025. McKemey, quien anteriormente se desempeñó como jefe de Transformación Empresarial en IQVIA y Vicepresidente Senior de Soluciones de Estrategia de I+D en Quintiles, aporta más de 25 años de experiencia en investigación y desarrollo.
El nombramiento es parte de una transición de liderazgo planificada, con Patrick Smith, PharmD, asumiendo el rol de Vicepresidente Senior de Ciencias Traslacionales. McKemey tiene una licenciatura y un doctorado en Física de Partículas Nucleares de Alta Energía por la Universidad de Londres, y ha trabajado anteriormente como Principal en la práctica de Ciencias de la Vida del Boston Consulting Group.
La empresa tiene como objetivo aprovechar la experiencia de McKemey para acelerar el crecimiento de sus servicios de biosimulación y científicos para clientes de ciencias de la vida a nivel mundial, centrándose en mejorar los procesos de desarrollo de medicamentos y la toma de decisiones de cartera a través de modelos in silico.
Certara (NASDAQ: CERT)는 Dr. Adrian McKemey를 2025년 3월 3일부터 약물 개발 솔루션의 사장으로 임명했습니다. McKemey는 이전에 IQVIA의 기업 혁신 책임자 및 Quintiles의 R&D 전략 솔루션의 수석 부사장을 역임했으며, 연구 및 개발 분야에서 25년 이상의 경험을 보유하고 있습니다.
이번 임명은 계획된 리더십 전환의 일환으로, Patrick Smith, PharmD가 번역 과학의 수석 부사장 역할로 이동합니다. McKemey는 런던 대학교에서 고에너지 핵입자 물리학 학사 및 박사 학위를 취득했으며, 이전에는 보스턴 컨설팅 그룹의 생명과학 부문에서 원장으로 근무했습니다.
회사는 McKemey의 전문성을 활용하여 전 세계 생명과학 고객을 위한 바이오 시뮬레이션 및 과학 서비스의 성장을 가속화하고, in silico 모델을 통해 약물 개발 프로세스 및 포트폴리오 의사 결정을 개선하는 데 중점을 두고 있습니다.
Certara (NASDAQ: CERT) a nommé Dr. Adrian McKemey président des solutions de développement de médicaments, à compter du 3 mars 2025. McKemey, qui a précédemment occupé le poste de responsable de la transformation d'entreprise chez IQVIA et de vice-président senior des solutions stratégiques R&D chez Quintiles, apporte plus de 25 ans d'expérience en recherche et développement.
Cette nomination s'inscrit dans le cadre d'une transition de leadership planifiée, avec Patrick Smith, PharmD, qui passe au rôle de vice-président senior des sciences translationnelles. McKemey est titulaire d'une licence et d'un doctorat en physique des particules nucléaires à haute énergie de l'Université de Londres et a précédemment travaillé comme principal dans la pratique des sciences de la vie du Boston Consulting Group.
L'entreprise vise à tirer parti de l'expertise de McKemey pour accélérer la croissance de ses services de biosimulation et scientifiques pour les clients des sciences de la vie à l'échelle mondiale, en se concentrant sur l'amélioration des processus de développement de médicaments et de la prise de décision de portefeuille grâce à des modèles in silico.
Certara (NASDAQ: CERT) hat Dr. Adrian McKemey zum Präsidenten der Lösungen für die Arzneimittelentwicklung ernannt, mit Wirkung zum 3. März 2025. McKemey, der zuvor als Leiter der Unternehmensumwandlung bei IQVIA und als Senior VP für R&D-Strategielösungen bei Quintiles tätig war, bringt über 25 Jahre Erfahrung in Forschung und Entwicklung mit.
Die Ernennung ist Teil eines geplanten Führungsübergangs, bei dem Patrick Smith, PharmD, die Rolle des Senior Vice President für Translationale Wissenschaften übernimmt. McKemey hat einen BSc und einen PhD in Hochenergie-Nuklear-Teilchenphysik von der University of London und arbeitete zuvor als Principal in der Life Sciences-Praxis der Boston Consulting Group.
Das Unternehmen hat zum Ziel, McKemeys Expertise zu nutzen, um das Wachstum seiner Biosimulations- und wissenschaftlichen Dienstleistungen für Kunden in den Lebenswissenschaften weltweit zu beschleunigen, mit einem Fokus auf die Verbesserung der Arzneimittelentwicklungsprozesse und der Portfolioentscheidung durch in silico Modelle.
- Strategic hire with 25+ years of R&D experience
- Planned leadership transition maintaining continuity
- Expansion of scientific services and biosimulation capabilities
- None.
McKemey joins Certara to accelerate growth of its strategic drug development solutions
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists.
Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with the Boston Consulting Group (BCG) working in the Life Sciences practice in New York. He holds a BSc (First Class) and a PhD in High Energy Nuclear Particle Physics from the University of London.
The change is part of a planned leadership transition. Patrick Smith, PharmD. will continue to support Certara’s growth in science and innovation as Senior Vice President of Translational Sciences. Patrick and his leadership team successfully led and integrated the Certara services team building a unified offering of comprehensive scientific services for life sciences clients across the globe.
“Adrian brings a mission-driven approach to improving drug development,” said William Feehery, Ph.D., Certara’s CEO. “His leadership will build upon recent accomplishments helping Certara further scale its biosimulation and scientific services to support the next generation of life-changing therapies.”
“Certara’s leadership in biosimulation is key to de-risking the thorny issues I have seen the industry tackle for decades in clinical development. The rising adoption of in silico models into portfolio decision making can improve the probability of success at the asset and aggregate portfolio level,” said Adrian McKemey. “This role and the Certara portfolio present an ideal opportunity for me to positively impact the industry and accelerate medicines to patients.”
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.
Certara Contact:
Sheila Rocchio
sheila.rocchio@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com
FAQ
When will Dr. Adrian McKemey start as President of Drug Development Solutions at Certara (CERT)?
What is Dr. Adrian McKemey's professional background before joining Certara (CERT)?
What will happen to Patrick Smith's role at Certara (CERT) following McKemey's appointment?
What are the main objectives for Dr. McKemey's role at Certara (CERT)?
